BridgeBio Pharma, Inc.
BBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $681 | $376 | $377 | $394 |
| Short-Term Investments | $0 | $59 | $95 | $443 |
| Receivables | $5 | $2 | $17 | $20 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $35 | $41 | $60 | $32 |
| Total Curr. Assets | $721 | $478 | $549 | $889 |
| Property Plant & Equip (Net) | $13 | $20 | $25 | $46 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $24 | $26 | $29 | $45 |
| Long-Term Investments | $144 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $18 | $23 | $20 | $33 |
| Total NC Assets | $199 | $69 | $74 | $124 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $919 | $546 | $623 | $1,013 |
| Liabilities | – | – | – | – |
| Payables | $10 | $11 | $12 | $12 |
| Short-Term Debt | $5 | $4 | $4 | $5 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $6 | $8 | $0 |
| Other Curr. Liab. | $140 | $123 | $98 | $118 |
| Total Curr. Liab. | $154 | $144 | $121 | $135 |
| LT Debt | $1,726 | $1,736 | $1,720 | $1,721 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $496 | $9 | $27 | $22 |
| Total NC Liab. | $2,223 | $1,745 | $1,747 | $1,743 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $9 | $13 | $16 | $22 |
| Total Liabilities | $2,377 | $1,889 | $1,868 | $1,878 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$3,096 | -$2,561 | -$1,918 | -$1,437 |
| AOCI | $0 | $0 | -$0 | -$0 |
| Other Equity | $1,628 | $1,206 | $664 | $567 |
| Total Equity | -$1,468 | -$1,354 | -$1,255 | -$870 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $10 | $12 | $10 | $5 |
| Total Liab. & Tot. Equity | $919 | $546 | $623 | $1,013 |
| Net Debt | $1,049 | $1,364 | $1,347 | $1,332 |